Targeting eEF2 with the protein translation elongation inhibitor SVC112 in head and neck squamous cancer

使用蛋白质翻译延伸抑制剂 SVC112 靶向 eEF2 治疗头颈鳞状细胞癌

基本信息

  • 批准号:
    10704601
  • 负责人:
  • 金额:
    $ 32.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-01 至 2026-08-31
  • 项目状态:
    未结题

项目摘要

SUMMARY. Radiation therapy (RT) and immunotherapy with PD-1 inhibitors are used in early and relapsed head and neck squamous cell cancers (HNSCC), respectively; RT failures are common, and most patients do not respond to PD-1 inhibition. Both impact the tumor microenvironment (TME), but studying the TME is limited by the availability of models with human immune cells. PI3K/mTOR signaling regulates protein synthesis through transcription factors such as Myc or SOX2, that dictate growth, invasion, and drug resistance in HNSCC. SVC112 is a fully synthetic small molecule that inhibits protein synthesis at the elongation step by inhibiting eEF2. SVC112 had greater effect on cancer over non-cancer cells, and was more potent and selective than homoharringtonin (HHT), an FDA-approved translation elongation inhibitor. Cancer cells had higher eEF2 than non-cancer cells, and the most susceptible strain had the highest eEF2 expression. SVC112 depleted SOX2, Myc, and Cyclin D1 in HNSCC cells at concentrations that had minimal effect on the rest of the proteome. SVC112 decreased spheres in vitro, reduced tumor growth in vivo in patient-derived xenografts (PDX), and induced tumor regression when given with RT in three out of four PDX models. SVC112 also reduced the E6 oncoprotein in human papillomavirus-driven cells. Lastly, SVC112 decreased PD-1 ligand (PD-L1) resulting in decreased PD-L1:PD-1 interactions leading to increased sphere T cell invasion, while having no effect on T cell fitness or function. Thus, SVC112 can target multiple key pathways (SOX2, Myc, PD-L1), and can influence the TME to reverse immune evasion. To test SVC112’s therapeutic potential in HNSCC, several unique tools will be used including 1) spheres containing cancer cells and T cells (iSpheres) that enable studying TME interactions and immunotherapy in vitro, 2) syngeneic mouse models of HNSCC, and 3) humanized mouse (HM) models, developed by the PI, that enable studying TME interactions and immunotherapy in vivo. The hypothesis that SVC112’s discriminating effect is due to selective depletion of key proteins will be tested by ribosome profiling (to identify mRNA targets) and proteomics analysis (to identify proteins targets). Then, we will test the mechanism of SVC112 synergy with RT, and if the modulation of the TME by SVC112 will further enhance RT efficacy. Lastly, the hypothesis that reduction of PD-L1 by SVC112 in HNSCC will alter the tumor-immune interaction will be tested by defining the effect of SVC112 on the expression of proteins critical for the TME, T cell tumor infiltration, and cancer-immune crosstalk. The effect of SVC112 on T cell fitness and function will be examined, aiding SVC112 translation. We will assess SVC112 and PD-1 inhibition in iSphere and HM models, and explore their efficacy when both are combined. Lastly, we will test the predictive value of eEF2 in SVC112 susceptibility, and we will assess eEF2 expression in human tumors, to enable identifying a companion biomarker to SVC112, using a HNSCC tissue bank with 1,250 patient cases. This project will propel the translation of SVC112, a drug discovered in Colorado, by dissecting the basis for its effect, studying its toxicity, and testing predictive biomarkers to aid clinical trials.
总结。放射治疗(RT)和PD-1抑制剂免疫治疗用于早期和复发

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Antonio Jimeno其他文献

Antonio Jimeno的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Antonio Jimeno', 18)}}的其他基金

Colorado Head and Neck Cancer SPORE
科罗拉多头颈癌孢子
  • 批准号:
    10868331
  • 财政年份:
    2023
  • 资助金额:
    $ 32.82万
  • 项目类别:
Targeting eEF2 with the protein translation elongation inhibitor SVC112 in head and neck squamous cancer
使用蛋白质翻译延伸抑制剂 SVC112 靶向治疗头颈鳞状细胞癌中的 eEF2
  • 批准号:
    10477463
  • 财政年份:
    2021
  • 资助金额:
    $ 32.82万
  • 项目类别:
Colorado HNC SPORE Administrative Core
科罗拉多州 HNC SPORE 行政核心
  • 批准号:
    10704582
  • 财政年份:
    2021
  • 资助金额:
    $ 32.82万
  • 项目类别:
Colorado HNC SPORE Administrative Core
科罗拉多州 HNC SPORE 行政核心
  • 批准号:
    10477442
  • 财政年份:
    2021
  • 资助金额:
    $ 32.82万
  • 项目类别:
Colorado Head and Neck Cancer SPORE
科罗拉多头颈癌孢子
  • 批准号:
    10704550
  • 财政年份:
    2021
  • 资助金额:
    $ 32.82万
  • 项目类别:
Targeting eEF2 with the protein translation elongation inhibitor SVC112 in head and neck squamous cancer
使用蛋白质翻译延伸抑制剂 SVC112 靶向治疗头颈鳞状细胞癌中的 eEF2
  • 批准号:
    10268847
  • 财政年份:
    2021
  • 资助金额:
    $ 32.82万
  • 项目类别:
Colorado HNC SPORE Administrative Core
科罗拉多州 HNC SPORE 行政核心
  • 批准号:
    10268842
  • 财政年份:
    2021
  • 资助金额:
    $ 32.82万
  • 项目类别:
Targeting oncogenic Myb fusions in salivary gland cancer with the elongation inhibitor SVC112
使用延伸抑制剂 SVC112 靶向唾液腺癌中的致癌 Myb 融合
  • 批准号:
    10368161
  • 财政年份:
    2021
  • 资助金额:
    $ 32.82万
  • 项目类别:
Colorado Head and Neck Cancer SPORE
科罗拉多头颈癌孢子
  • 批准号:
    10268841
  • 财政年份:
    2021
  • 资助金额:
    $ 32.82万
  • 项目类别:
Targeting oncogenic Myb fusions in salivary gland cancer with the elongation inhibitor SVC112
使用延伸抑制剂 SVC112 靶向唾液腺癌中的致癌 Myb 融合
  • 批准号:
    10592292
  • 财政年份:
    2021
  • 资助金额:
    $ 32.82万
  • 项目类别:

相似海外基金

How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.82万
  • 项目类别:
    Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 32.82万
  • 项目类别:
    Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 32.82万
  • 项目类别:
    Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.82万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.82万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 32.82万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 32.82万
  • 项目类别:
    Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 32.82万
  • 项目类别:
    Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
  • 批准号:
    23K00129
  • 财政年份:
    2023
  • 资助金额:
    $ 32.82万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
  • 批准号:
    2883985
  • 财政年份:
    2023
  • 资助金额:
    $ 32.82万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了